CN113383012A - 人肝细胞生长因子突变体及其应用 - Google Patents

人肝细胞生长因子突变体及其应用 Download PDF

Info

Publication number
CN113383012A
CN113383012A CN202080007253.5A CN202080007253A CN113383012A CN 113383012 A CN113383012 A CN 113383012A CN 202080007253 A CN202080007253 A CN 202080007253A CN 113383012 A CN113383012 A CN 113383012A
Authority
CN
China
Prior art keywords
mutant
hhgf
vector
hgf
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080007253.5A
Other languages
English (en)
Inventor
聂李亚
许松山
马素永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Northland Biotech Co Ltd
Original Assignee
Beijing Northland Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Northland Biotech Co Ltd filed Critical Beijing Northland Biotech Co Ltd
Publication of CN113383012A publication Critical patent/CN113383012A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

提供了人肝细胞生长因子(hHGF)的突变体，还提供编码所述突变体的核酸分子，含有所述核酸分子的载体，含有所述核酸分子或载体的宿主细胞；同时提供含有所述hHGF突变体或编码所述突变体的核酸分子的药物组合物，以及所述hHGF突变体或编码所述突变体的核酸分子的用途。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080007253.5A 2019-01-07 2020-01-02 人肝细胞生长因子突变体及其应用 Pending CN113383012A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910010091.XA CN109535243B (zh) 2019-01-07 2019-01-07 人肝细胞生长因子突变体及其应用
PCT/CN2020/070010 WO2020143515A1 (zh) 2019-01-07 2020-01-02 人肝细胞生长因子突变体及其应用

Publications (1)

Publication Number Publication Date
CN113383012A true CN113383012A (zh) 2021-09-10

Family

ID=65834432

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910010091.XA Active CN109535243B (zh) 2019-01-07 2019-01-07 人肝细胞生长因子突变体及其应用
CN202080007253.5A Pending CN113383012A (zh) 2019-01-07 2020-01-02 人肝细胞生长因子突变体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910010091.XA Active CN109535243B (zh) 2019-01-07 2019-01-07 人肝细胞生长因子突变体及其应用

Country Status (6)

Country Link
US (1) US20220064242A1 (zh)
EP (1) EP3909974A4 (zh)
JP (1) JP7246494B2 (zh)
KR (1) KR102667727B1 (zh)
CN (2) CN109535243B (zh)
WO (1) WO2020143515A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN110606883A (zh) * 2019-07-25 2019-12-24 广州凌腾生物医药有限公司 肝细胞生长因子的制备方法
WO2022226176A2 (en) * 2021-04-23 2022-10-27 Plantible Foods Inc. Ribulose-1,5-bisphosphate carboxylate-oxygenase (rubisco) protein isolate compositions for plant-based egg replacement products and plant-based milk replacement products
WO2023217267A1 (zh) * 2022-05-13 2023-11-16 上海瑞宏迪医药有限公司 包含utr的核酸构建体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7343898A (en) * 1997-05-10 1998-12-08 Imperial Cancer Research Technology Limited Hgf polypeptides and their use in therapy
CN1284563A (zh) * 1999-08-17 2001-02-21 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组载体及其在缺血性疾病中的应用
AU2002251337B2 (en) * 2001-04-27 2007-08-02 Cambridge University Technical Services Limited The NK1 fragment of hepatocyte growth factors/scatter factor (HGF/SF) and variants thereof, and their use
CN106714832A (zh) * 2014-07-03 2017-05-24 英克隆有限责任公司 用于胃肠道间质瘤的疗法
CN109535243A (zh) * 2019-01-07 2019-03-29 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN110577954A (zh) * 2019-10-12 2019-12-17 北京万福来生物技术有限责任公司 突变的肝细胞生长因子基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118012A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
JPH1027951A (ja) * 1996-07-12 1998-01-27 Oki Electric Ind Co Ltd 配線構造
EP1036566B1 (en) * 1997-12-03 2007-09-05 Nakamura, Toshikazu Preparation for continuous intravenous administration
WO2006105511A1 (en) * 2005-03-31 2006-10-05 The General Hospital Corporation Monitoring and modulating hgf/hgfr activity
JP5419045B2 (ja) * 2007-02-28 2014-02-19 学校法人慶應義塾 脊髄損傷治療薬剤
WO2008105088A1 (ja) 2007-02-28 2008-09-04 Keio University 脊髄損傷治療薬剤
DK3192524T3 (da) * 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
CN108424459A (zh) 2017-02-14 2018-08-21 上海交通大学医学院 人血清白蛋白与人突变型肝细胞生长因子的融合蛋白及其制备方法和应用
CN108611367B (zh) 2018-04-24 2019-11-19 北京诺思兰德生物技术股份有限公司 一类通过质粒载体介导的基因治疗重组载体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7343898A (en) * 1997-05-10 1998-12-08 Imperial Cancer Research Technology Limited Hgf polypeptides and their use in therapy
CN1284563A (zh) * 1999-08-17 2001-02-21 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组载体及其在缺血性疾病中的应用
AU2002251337B2 (en) * 2001-04-27 2007-08-02 Cambridge University Technical Services Limited The NK1 fragment of hepatocyte growth factors/scatter factor (HGF/SF) and variants thereof, and their use
CN106714832A (zh) * 2014-07-03 2017-05-24 英克隆有限责任公司 用于胃肠道间质瘤的疗法
CN109535243A (zh) * 2019-01-07 2019-03-29 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN110577954A (zh) * 2019-10-12 2019-12-17 北京万福来生物技术有限责任公司 突变的肝细胞生长因子基因及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李孝圭等: "人肝细胞生长因子cDNA的克隆及其在Pichia系统中的表达", 《药物生物技术》 *

Also Published As

Publication number Publication date
WO2020143515A1 (zh) 2020-07-16
EP3909974A4 (en) 2022-05-04
KR20210141453A (ko) 2021-11-23
JP7246494B2 (ja) 2023-03-27
EP3909974A1 (en) 2021-11-17
KR102667727B1 (ko) 2024-05-20
CN109535243B (zh) 2019-09-24
CN109535243A (zh) 2019-03-29
US20220064242A1 (en) 2022-03-03
JP2022522941A (ja) 2022-04-21

Similar Documents

Publication Publication Date Title
CN113383012A (zh) 人肝细胞生长因子突变体及其应用
RU2741345C2 (ru) Белки с двойной функцией и содержащая их фармацевтическая композиция
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
CA2259163C (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
RU2741087C2 (ru) Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция
ES2304811T3 (es) Fragmentos del factor de crecimiento de tejido conjuntivo.
US8324160B2 (en) Chimeric polypeptides and uses thereof
US10293043B2 (en) Methods of lowering serum cholesterol
JP2007209349A (ja) 新規な神経栄養因子
KR100334739B1 (ko) 절단된신경교세포주-유래신경영양성인자단백질산물
EA032727B1 (ru) Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2015031316A1 (en) Methods of using interleukin-10 for treating diseases and disorders
JP2009221207A (ja) Ｋｇｆポリペプチド組成物
AU2008256550B2 (en) VEGF-D mutants and their use
US6468970B2 (en) Analogs of NT-3
WO2015103782A1 (en) Fgf21 mutant and conjugate thereof
EA041758B1 (ru) Fgf21 мутанты и их применение
MXPA99000372A (en) Products analogues of proteins cationi

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210910